At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

WuXi Biologics subsidiary WuXi Vaccines has agreed to sell its vaccine manufacturing facility in Dundalk, Ireland, to MSD for approximately $500m. Expected to close in the first half of 2025, the deal ...

The employees at WuXi Biologics have once again shown their commitment to the local community with their fourth annual ...

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global uncertainties.

The New Jersey company was a natural buyer of the facility as it was the lone client WuXi Biologics served at the site in Dundalk, executing a 20-year contract to produce vaccines worth $150 ...

The Chinese contract drugmaker will sell its vaccine factory in Dundalk, Ireland, to U.S.-based Merck for about $500 million, it said in an exchange filing late Monday. The facility, with a net ...

The WuXi Biologics facility is located in Dundalk, Co Louth, in the IDA Science and Technology Park. WuXi invested €200 million in 2019 to build the plant, which currently employs 200 people ...

The Dundalk site will become part of the company’s network of five, large-scale pharma manufacturing sites China's WuXi Biologics is to sell its vaccine manufacturing site in Dundalk to MSD ...

WuXi Biologics Cayman Inc. will sell a vaccine ... while continuing to navigate geopolitical tensions. The site at Dundalk, Ireland, which has been under construction since 2019, was designed ...

WuXi has separate biologics facilities at the site that will continue to operate. MSD said the Dundalk deal further diversified the group’s network in Ireland, where each of its eight sites ...